TABLE 1.
Model system | Reference | Effect on tumor size | Effect on angiogenesis |
Vegf-A/angiogenic gene expression |
Conditions for gene silencing/inducible overexpression | p53 status | |
---|---|---|---|---|---|---|---|
In vivo | In vitro | ||||||
Tumor models | |||||||
TPA-DMBA chemical carcinogenesis in TAp73−/− mice | 11 | Larger tumors | Increased | ||||
Eμ-Myc transgenic mouse lymphomagenesis in TAp73−/− mice | 12 | Increased | |||||
E1a/Ras-transformed TAp73−/− MEFs in nude/Scid mice | 12 | Larger tumors | Increased | Increased | Increased | ||
13 | Smaller tumors | Decreased | Decreased | Wild type | |||
Xenograft model in nude mice with H1299 cells with TAp73 silencing | 11 | Larger tumors | Increased | Increased | Increasedb | Stable | Null |
13 | Decreased | Transient | Null | ||||
Xenograft model in nude/Scid mice with H1299/SAOS2 cells with inducible TAp73 expression | 11 | Smaller tumors (SAOS2) | Decreased (H1299) | Long term, from initiation of tumors (5 weeks) | Null | ||
13 | No difference (H1299 and SAOS2) | Increased | Increased (SAOS2) | Transient (6 days after tumor establishment) | Null | ||
Other models | |||||||
Aorta ring from TAp73−/− mice | 11 | Increased | |||||
Retina and iPSC from total p73−/− mice and MSC with p73DD | 15 | Decreased in all cases | Decreased in retina | Decreased in MSC | |||
HUVEC cells with p73DD overexpression or total p73 or TAp73 silencing | 15 | Decreased (p73DD and total p73 silenced) and no difference (TAp73 silenced) | Decreased in all cases | Transient | Wild type |
Data from articles that demonstrate an inhibitory role for TAp73 in angiogenesis are in boldface. Data from reports on TAp73 as a positive regulator of angiogenesis are in lightface. A cell without data represents data not provided in the article.
From reference 12.